Looks like efficacy seen in renal cell carcinoma , bone mets from an unknown primary cancer and non small cell lung cancer . NSCLC is one of the most common cancers . All patients had exhausted all approved treatments . Renal cell patient now in good health and the NSCLC patient is still to receive another cycle in late Feb .
